A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70095 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Xiaomeng Mao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Healthy Volunteers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca, Sanofi.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory tract disease in infants; however, global nirsevimab trials did not enroll Chinese infants. To inform the investigation of nirsevimab for the prevention of RSV LRTI in Chinese infants, this Phase I, randomized, placebo‐controlled trial evaluated the pharmacokinetics (PK) and safety of nirsevimab in healthy Chinese adults. Participants were randomized 3:1 to a single 300 mg intramuscular dose of nirsevimab or placebo and were followed through 150 days post‐dose. Serum nirsevimab concentrations were measured and PK parameters of maximum serum concentration ( C max ), time to maximum concentration ( t max ), and area under the concentration‐time curve from time 0 to Day 150 (AUC 0–150 ) were estimated. Treatment emergent adverse events (AEs), clinical laboratory data, and vital signs were evaluated. Overall, 24 participants were randomized to nirsevimab ( n = 18) or placebo ( n = 6). Nirsevimab geometric mean (coefficient of variation [%CV]) C max was 46.9 (21.7) μg/mL, median (range) t max was 7.0 (4.9, 29.9) days, and geometric mean (%CV) AUC 0–150 was 4210.6 (13.6) μg·day/mL. Treatment‐emergent AEs (all Grade 1 or Grade 2 in severity) were reported in 5/18 (27.8%) nirsevimab recipients and 2/6 (33.3%) placebo recipients. No serious AEs, new onset chronic disease, or deaths were reported. Overall, safety and PK outcomes were consistent with those observed in healthy adults in the USA, with no new safety concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
- Clinical Development, Respiratory & Immunology, R&D China, AstraZeneca, Shanghai, China.
- Biometrics, R&D China, AstraZeneca, Shanghai, China.
- Clinical Safety, R&D China, AstraZeneca, Shanghai, China.
- Development Operations, R&D China, AstraZeneca, Shanghai, China.
- Clinical Pharmacology and Quantitative Pharmacology, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
ORCID-Profile: Xiaoyun Ge, Ulrika Wählby Hamrén, Yuwen Jin
Förderung
- AstraZeneca
- Sanofi
Zitieren
APA
Mao, X., Hua, X., Wu, C., Ge, X., Zhang, J., Wu, X., Kubiak, R. J., Wählby Hamrén, U., Villafana, T., Christou, G., Green, J., Takas, T., & Jin, Y. (2025). A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults. Clinical and Translational Science. https://doi.org/10.1111/cts.70095
Vancouver
Mao X, Hua X, Wu C, Ge X, Zhang J, Wu X, et al. A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults. Clinical and Translational Science. 2025. doi:10.1111/cts.70095
BibTeX
@article{Mao2025,
author = {Mao, Xiaomeng and Hua, Xiaohan and Wu, Chengyi and Ge, Xiaoyun and Zhang, Jie and Wu, Xiaojie and Kubiak, Robert J and Wählby Hamrén, Ulrika and Villafana, Tonya and Christou, Georgios and Green, Jannine and Takas, Therese and Jin, Yuwen},
title = {A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70095}
}
EUVIMED